Bone Index, a Finland-based medtech company, has secured a significant financing round led by Lynx Financial, with participation from other European investors and existing shareholders. The investment showcases the company’s commitment to expanding its product offerings globally.
About Bone Index
- Founded back in 2011, Bone Index is a medical device firm with the goal to create technology for osteoporosis diagnosis and screening. Its main offering, Bindex®, is a portable instrument made to evaluate bone health fast and precisely in point-of-care situations.
- By aiding in the early detection of osteoporosis, the company's technology may help lower the frequency of fractures and enhance surgical outcomes. Bone Index states that its work is especially important in the US, where osteoporosis is a major public health concern.
Investment details
The fresh investment round was provided by Lynx Financial, a Chinese healthcare and life science-focused fund, investing in innovative companies in western countries in both therapeutics and medical technology areas.
“We are excited about the potential of Bone Index’s innovative diagnostics technology. Bone Index’s solution is accurate and accessible and can democratize the way osteoporosis is detected and diagnosed for consumers and patients,” Donald Xu, Managing Director of Lynx Financial, stated.
Although the exact of the deal was not disclosed, Lynx Financial’s investments usually range from $10 million to $20 million. Therefore, the deal amount should fall in this range.
Bone Index plans to use funds to expand its distribution and service capabilities in North America and Asia Pacific, enhancing infrastructure and meeting growing demand for bone health diagnostics solutions.
